{
    "accessibility": "Open access",
    "additionDate": "2021-01-18T10:29:56Z",
    "biotoolsCURIE": "biotools:covid19-drug-interactions",
    "biotoolsID": "covid19-drug-interactions",
    "collectionID": [
        "COVID-19"
    ],
    "confidence_flag": "tool",
    "cost": "Free of charge",
    "credit": [
        {
            "email": "khoo@liverpool.ac.uk",
            "name": "Saye Khoo",
            "typeEntity": "Person"
        }
    ],
    "description": "COVID-19 Drug interactions is a comprehensive, up-to-date, evidence-based COVID19 drug-drug interaction resource.",
    "editPermission": {
        "type": "private"
    },
    "function": [
        {
            "operation": [
                {
                    "term": "Data retrieval",
                    "uri": "http://edamontology.org/operation_2422"
                },
                {
                    "term": "Database search",
                    "uri": "http://edamontology.org/operation_2421"
                }
            ]
        }
    ],
    "homepage": "http://www.covid19-druginteractions.org",
    "lastUpdate": "2021-03-03T19:28:42Z",
    "name": "COVID- 19 Drug interactions",
    "owner": "Kigaard",
    "publication": [
        {
            "doi": "10.1093/JAC/DKAA340",
            "metadata": {
                "abstract": "Â© The Author(s) 2020.As global health services respond to the coronavirus pandemic, many prescribers are turning to experimental drugs. This review aims to assess the risk of drug-drug interactions in the severely ill COVID-19 patient. Experimental therapies were identified by searching ClinicalTrials.gov for 'COVID-19', '2019-nCoV', '2019 novel coronavirus' and 'SARS-CoV-2'. The last search was performed on 30 June 2020. Herbal medicines, blood-derived products and in vitro studies were excluded. We identified comorbidities by searching PubMed for the MeSH terms 'COVID-19', 'Comorbidity' and 'Epidemiological Factors'. Potential drug-drug interactions were evaluated according to known pharmacokinetics, overlapping toxicities and QT risk. Drug-drug interactions were graded GREEN and YELLOW: no clinically significant interaction; AMBER: Caution; RED: Serious risk. A total of 2378 records were retrieved from ClinicalTrials.gov, which yielded 249 drugs that met inclusion criteria. Thirteen primary compounds were screened against 512 comedications. A full database of these interactions is available at www.covid19-druginteractions.org. Experimental therapies for COVID-19 present a risk of drug-drug interactions, with lopinavir/ritonavir (10% RED, 41% AMBER; mainly a perpetrator of pharmacokinetic interactions but also risk of QT prolongation particularly when given with concomitant drugs that can prolong QT), chloroquine and hydroxychloroquine (both 7% RED and 27% AMBER, victims of some interactions due to metabolic profile but also perpetrators of QT prolongation) posing the greatest risk. With management, these risks can be mitigated. We have published a drug-drug interaction resource to facilitate medication review for the critically ill patient.",
                "authors": [
                    {
                        "name": "Back D."
                    },
                    {
                        "name": "Boyle A."
                    },
                    {
                        "name": "Burger D."
                    },
                    {
                        "name": "Gibbons S."
                    },
                    {
                        "name": "Hodge C."
                    },
                    {
                        "name": "Khoo S."
                    },
                    {
                        "name": "Marra F."
                    },
                    {
                        "name": "Marzolini C."
                    },
                    {
                        "name": "Siccardi M."
                    }
                ],
                "citationCount": 12,
                "date": "2020-12-01T00:00:00Z",
                "journal": "Journal of Antimicrobial Chemotherapy",
                "title": "Drug interactions: A review of the unseen danger of experimental COVID-19 therapies"
            },
            "pmcid": "PMC7454591",
            "pmid": "32750131"
        }
    ],
    "toolType": [
        "Web application"
    ],
    "topic": [
        {
            "term": "Drug metabolism",
            "uri": "http://edamontology.org/topic_3375"
        },
        {
            "term": "Endocrinology and metabolism",
            "uri": "http://edamontology.org/topic_3407"
        },
        {
            "term": "Oncology",
            "uri": "http://edamontology.org/topic_2640"
        },
        {
            "term": "Pharmacology",
            "uri": "http://edamontology.org/topic_0202"
        },
        {
            "term": "Public health and epidemiology",
            "uri": "http://edamontology.org/topic_3305"
        }
    ]
}
